Pharmacological modulation of procoagulant microparticles improves haemodynamic dysfunction during septic shock in rats

Thrombosis and Haemostasis

Volumn 111, Issue 1, 2013, Pages 154-164

  Boisramé Helms, Julie ^a,b   Delabranche, Xavier ^a,b   Degirmenci, Su Emmanuelle ^b   Zobairi, Fatiha ^c   Berger, Asael ^a,b   Meyer, Grégory ^c   Burban, Mélanie ^c   Mostefai, Hadj Ahmed ^a   Levy, Bruno ^d   Toti, Florence ^c   Meziani, Ferhat ^a,b  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d INSERM   (France)

Author keywords

Activated protein C; Haemodynamic dysfunction; Inflammation; Microparticles; Septic shock

Indexed keywords

ACTIVATED PROTEIN C; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTIC ACID; THROMBOXANE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART RATE; HEMODYNAMIC PARAMETERS; HYPOTENSION; INFLAMMATION; LAPAROTOMY; MALE; MEAN ARTERIAL PRESSURE; MEMBRANE MICROPARTICLE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SEPTIC SHOCK; WESTERN BLOTTING;

ACTIVATED PROTEIN C; HAEMODYNAMIC DYSFUNCTION; INFLAMMATION; MICROPARTICLES; SEPTIC SHOCK;

ANIMALS; CELL-DERIVED MICROPARTICLES; COAGULANTS; CYCLOOXYGENASE 2; HEMODYNAMICS; HUMANS; INFLAMMATION; MALE; NF-KAPPA B; PHENOTYPE; PROTEIN C; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SHOCK, SEPTIC; THROMBOPLASTIN; THROMBOXANE A2; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891877247     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0313     Document Type: Article

References (46)

1. Annane D, et al. Septic shock. Lancet 2005; 365: 63-78.
2. Boisramé-Helms J, et al. Endothelial dysfunction in sepsis. Curr Vasc Pharmacol 2013; 11: 150-160.
3. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med 2012; 40: 2704-2708.
4. Morel O, et al. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol 2011; 33: 469-486.
5. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010; 107: 1047-1057.
6. Morel O, et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-164.
7. Meziani F, et al. Bench-to-bedside review: circulating microparticles--a new player in sepsis? Crit Care 2010; 14: 236.
8. Nieuwland R, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-935.
9. Mortaza S, et al. Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats. Crit Care Med 2009; 37: 2045-2050.
10. Berckmans RJ, et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646.
11. Rautou PE, et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011; 109: 593-606.
12. Egorina EM, et al. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood 2008; 111: 1208-1216.
13. Van Der Meijden PE, et al. Platelet-and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-1362.
14. Mosnier LO, et al. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
15. Montes R, et al. Activated protein C: reasons to believe. J Thromb Haemost 2012; 10: 1733-1735.
16. Sennoun N, et al. Recombinant human activated protein C improves endotoxemia-induced endothelial dysfunction: a blood-free model in isolated mouse arteries. Am J Physiol Heart Circ Physiol 2009; 297: H277-282.
17. Sennoun N, et al. Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 2009; 37: 246-255.
18. Dhainaut JF, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Journal of thrombosis and haemostasis: JTH 2004; 2: 1924-1933.
19. Kerschen EJ, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439-2448.
20. Mosnier LO, et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 2009; 113: 5970-5978.
21. Russo A, et al. Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv 2009; 9: 87-96.
22. Rezaie AR. The occupancy of endothelial protein C receptor by its ligand modulates the par-1 dependent signaling specificity of coagulation proteases. IUBMB Life 2011; 63: 390-396.
23. Weiler H. Multiple receptor-mediated functions of activated protein C. Hamostaseologie 2011; 31: 185-195.
24. Mosnier LO, et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 2012; 120: 5237-5246.
25. Perez-Casal M, et al. Activated protein C induces the release of microparticleassociated endothelial protein C receptor. Blood 2005; 105: 1515-1522.
26. Perez-Casal M, et al. The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Crit Care 2011; 15: R195.
27. Hubbard WJ, et al. Cecal ligation and puncture. Shock 2005; 24 (Suppl 1): 52-57.
28. Hugel B, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1846-1847.
29. Boulanger CM, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-2652.
30. Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension 2004; 43: 428-433.
31. Tesse A, et al. Upregulation of proinflammatory proteins through NF-kappaB pathway by shed membrane microparticles results in vascular hyporeactivity. Arterioscler Thromb Vasc Biol 2005; 25: 2522-2527.
32. Dignat-George F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-673.
33. Joop K, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85: 810-820.
34. Delabranche X, et al. Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. Intensive Care Med 2013; epub ahead of print.
35. Brodsky SV, et al. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004; 286: H1910-1915.
36. Densmore JC, et al. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 2006; 26: 464-471.
37. Soriano AO, et al. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005; 33: 2540-2546.
38. Janiszewski M, et al. Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: A novel vascular redox pathway. Critical Care Med 2004; 32: 818-825.
39. Sen P, et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood 2011; 117: 3199-3208.
40. Bouwens EA, et al. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013; 11 (Suppl 1): 242-253.
41. Bae JS, et al. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost 2008; 6: 954-961.
42. Ghosh S, et al. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007; 282: 11849-11857.
43. Bhattacharya A, Cohen ML. Vascular contraction and relaxation to thrombin and trypsin: thrombomodulin preferentially attenuates thrombin-induced contraction. J Pharmacol Exp Ther 2000; 295: 284-290.
44. Mostefai HA, et al. Circulating microparticles from patients with septic shock exert protective role in vascular function. Am J Respir Crit Care Med 2008; 178: 1148-1155.
45. Barry OP, et al. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J Biol Chem 1999; 274: 7545-7556.
46. Ranieri VM, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-2064.